Clinical trial
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
NCT00423917 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00423917 |
|---|---|
| Title | Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer |
| Official title | Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | bevacizumab, fulvestrant |
| Enrollment | 36 |
| Start date | Aug 1, 2007 |
| Primary completion | Feb 1, 2009 |
| Completion | Jan 15, 2017 |
| First posted | Jan 18, 2007 |
| Last update posted | May 8, 2018 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: